

## INHIBITORS OF THE PROLIFERATION OF FUNGI OF THE SPECIES *Cryptococcus neoformans*


**PATENT: MD 4712 C1(2020.09.30)**  
**MD 4742 C1(2021.02.28)**

**AUTHORS: GORINCHOY Viorina, LOZAN Vasile, BURDUNIUC Olga,  
BALAN Greta, TSAPCOV Victor, GULEA Aurelian**


**APPLICATION FIELDS: Medicine – Pharmacy – Cosmetics.**

**AIM: Chemical synthesis, characterization of new synthetic antifungal agents with potential application in medicine.**

**SOLUTION: New polynuclear coordination compounds based on oxo-bridged salicylates have been obtained.**



compound 1



compound 2

Compound	Antifungal activity (MIC* / MFC**) ( $\mu\text{g/mL}$ ) <i>Cryptococcus neoformans</i> CECT 1043	
	MIC	MFC
Fluconazole	16.0	-
Proximal analogue	0.12	0.24
Claimed compound 1	0.10	0.20
Claimed compound 2	0.08	0.16

\*MIC – minimum inhibitory concentration.  
\*\*MFC – minimum fungicidal concentration.

**ADVANTAGES:** The described compounds manifest antifungal properties against *Cryptococcus neoformans* CECT 1043. These agents exceed 200-160 times the analogous characteristics of Fluconazole that is used in medical practice and 1.5-1.2 times the analogous characteristics of closest prior art. They can be used in medicine and veterinary medicine for the prevention and treatment of mycoses.

**IMPLEMENTATION STAGE: At laboratory level.**

**ACKNOWLEDGMENTS:** This research was supported by the *project: 20.80009.5007.04*